Etizolam (Depas) is a thienotriazolodiazepine derivative, similar in structure to brotizolam, that has been in clinical use in certain Asian and European countries since 1983 as a sedative-hypnotic drug. It has gathered some popularity on the new psychoactive substance (NPS) market in the UK and Europe. Etizolam is unlicensed in the UK although used as a prescribed medication in other countries such as India, Italy and Japan. A 1 mg tablet is equivalent to a 10 mg diazepam (Valium) tablet.
The adverse effects of etizolam therapy include confusion, disorientation, ataxia, slurred speech and delerium.
None required.
Measured by LC-MS/MS
Please contact laboratory for interpretation.
The laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital form part of the services provided by University Hospitals Birmingham and are UKAS (United Kingdom Accreditation Service) accredited to the ISO 15189:2012 standard. For a list of accredited tests and other information please visit the UKAS website using the following link: https://www.ukas.com/find-an-organisation/
Tests not appearing on the UKAS Schedule of Accreditation currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further test information, please visit the test database: http://www.heftpathology.com/frontpage/test-database.html.
Protection of personal information - Laboratory Medicine comply with the Trust Data Protection policy and have procedures in place to allow the Directorate and its employees to comply with the Data Protection act 1998 and associated best practice and guidance.
For further information contact Louise Fallon, Quality Manager, 0121 424 1235